Correction

This article refers to:

Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation

Article title: Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation

Authors: Bruneta, M., & Millán, O.

Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY

Bibliometrics: Volume 14, Number 12, pages 1467–1479

DOI: https://doi.org/10.1080/17512433.2021.1987882

When this article was published firstly, there was an error in tables and funding statement. These have been corrected as below.

Table 2. Chemokines in Renal and Liver allograft recipients.

Author, Year	Chemokine	N (Patients)	Performance	Clinical Application
KIDNEY TRANSPLANTATION
Tatapudi et al, 2004	CXCL10	58	Se100%; Sp78%; AUC 0.90	Diagnostic of AR
Matz M et al, 2006	CXCL10	76	Se71%; Sp 95%; AUC 0.85	Diagnostic of AR
Hu H etal, 2004	CXCL10 CXCL9	99 99	Se86%; Sp 91% Se 80%; Sp94%	Diagnostic of TCMR
Matz M et al, 2006	CXCL10	54	Se62%; Sp95%; AUC 0.77	Predicts TCMR (4-5days prior dysfunction.
Peng et al, 2008	CXCL10 CXCL9	215 215	Se 65%; SP97%; AUC 0.81 Se 84%; SP83%; AUC 0.90	Diagnostic of TCMR Diagnostic of TCMR
Hu H et al, 2009	CXCL10 CXCL10	113 113	Se 89%; SP81%; AUC 0.93 Se 85%; SP90%; AUC 0.92	Diagnostic of TCMR Diagnostic of TCMR
Hirt-Minkouwski et al, 2012	CXCL10 CXCL9	213 213	Se 63%; SP80%; AUC 0.74 Se 61%; SP72%; AUC 0.69	Diagnostic of TCMR Diagnostic of SCR and TCMR
Hricik et al, 2013	CXCL9 CXCL10	280 280	Se 87%; SP82%; AUC 0.86 Se 74%; SP86%; AUC 0.77	Diagnostic and predictive (30d prior GD) of TCMR
Rabant M et al, 2015	CXCL10 CXCL9	213 213	Se 70%; SP76%; AUC 0.80 Se 90%; SP88%; AUC 0.91	Diagnostic of TCMR Diagnostic of TCMR
Rabant M et al, 2016	CXCL10 CXCL9	300 300	AUC 0.74; Se 82.4%; Sp 56.0%; PPV 29%; NPV 97.1%	CXCL10:Cr levels at both 1m and 3m identified patients at higher risk and predicts TCMR, ABMR, SCR
Blydt-Hansen et al,2015	CXCL10 CXCL10	51	Se 77%; SP60%; AUC 0.88 Se 59%; SP67%; AUC 0.81	CXCL10:Cr Diagnostic of TCMR CXCL10:Cr Diagnostic of SCR
Ciftci et al, 2019	CXCL9 CXCL10	71	Se 0.79 Sp 0.88 AUC 0.95 Se 0.82 Sp 0.85 AUC 0.97	Diagnostic and prediction of TCMR
Millán et al, 2017	CXCL10	80	Se 0.84 Sp 0.80 AUC 0.87 PPV 90%; NPV 85%	Diagnostic and prognostic of TCMR Graft dysfunction (GFR)
Tinel et al, 2020	CXCL9 CXCL10	329	8-parameter model (recipient age, sex, estimated glomerular filtration rate, donor specific antibodies, UTI, BKV blood viral load, CXCL9 and CXCL10) Se 84.4% Sp 69.3 AUC 0.85 PPV46.6% NPV93.3%	Diagnostic of TCMR and confounding factors: BKV and urinary tract infection (UTI)
Weseslindtner et al, 2020	CXCL10	85	BKPyV DNAemia + rejection AUC: 0.85 151.94 pg/ml, P = 0.002	Diagnostic of AR and BKV replication may progress and polyomavirus-associated nephropathy confounding factors
Arnau et al, 2021	CXCL10/Cr	151	TCMR: Cutoff 13.3ng/mmol Se 72.2% Sp 67.8% AUC 0.72 sABMR: Cutoff 11.9ng/mmol Se 82.9% Sp 78.3% AUC 0.80	Diagnostic and prediction of TCMR and subclinical ABMR
LIVER TRANSPLANTATION
Friedman et al, 2012	CXCL19 CXCL10	73	-	Early allograft dysfunction
Raschzok et al, 2015	CXCL9	94	Se 60% Sp79% AUC 0.629 PPV 91% NPV 67%	Pre transplantation risk of rejection

Table 3. miRNAs in Renal and Liver allograft recipients.

Author, Year	miRNA	Biological Matrix	N (Patients)		Clinical Event	Function
KIDNEY TRANSPLANTATION
D.Anglicheau et al. 2009	Panel of 365 miRs	Graft biopsy		33, Kidney Tx	Acute Rejection	Up-regulation of miR-155-5p; miR-142-5p; miR-223; miR146a; miR-146b; miR-342
JM Lorenzen et al. 2011	miR-210; miR-10a; miR-10b	Urinary pellet		88, Kidney Tx	Acute Rejection	Down-regulation of miR210
O Millán et al. 2017	miR-155-5p; miR210; miR-142-3p	Urinary pellet		80, Kidney Tx	Acute Rejection	Up-regulation of miR-155-5p Down-regulation of miR210
MJ S Scian et al, 2011	miR-142-3p; miR-204; miR-107; miR-211; miR32	Graft biopsy Urine		81, Kidney Tx	IF/TA	Up-regulation of miR-142-3p; miR-32; Down-regulation:miR204; miR-107;miR-211
IZ Ben-Dov et al. 2012	miR-21; miR-142-3p and 5p; miR-506; miR-30a; and -30d.	Graft Biopsy		8, Kidney Tx	Acute Rejection	Up-regulation of miR-142-3p and-5p; miR-21; miR-506 Down-regulation of miR30b and 30c.
M Matz et al. 2016	miR-158; miR-16; miR-103a, miR-106a; miR-107	Blood		110, Kidney Tx	Acute Rejection	Down-regulation of miR-15B; miR-16; miR-103a; miR-106A and miR-107.
LIVER TRANSPLANTATION
WR Farid et al. 2012	miR-122; miR-148ª; miR-194	Graft biopsy Serum		45, Liver Tx	Acute Rejection	Up-regulation of miR-122; miR-148a; miR-194
RB Schumuck et al. 2017	miR-122; miR-133a; miR-148a; miR-194	Bile		56, Liver Tx	Acute Rejection	Up-regulation of miR-122; miR-133a; miR148a; miR-194.
A Shaked et al. 2017	miR-483-3p; miR-885-5p	Plasma		231, Liver Tx	Acute Rejection	Up-regulation of miR-483-3p; miR-885-5p;
Y Chen et al. 2012	miR-23b; miR-122; miR-150; Let-7c	Serum		40, Liver Tx	Occult HBV Infection	miR-23b; miR-122; miR-150; Let-7c
Blaya et al, 2018	miR-155	PBMC; Tissue		34, Liver Tx	Cirrhosis, Autoimmune hepatitis	Up regulation miR-155
Millán et al, 2019	miR-155 miR-181a miR-122	Plasma		145, Liver TX	TCMR SCR	Up regulation miR-155 and miR-181a Pre and Post TX
Ruíz et al, 2020	miR-155 miR-181a miR-122 miR-148	Plasma		145, Liver TX	TCMR Graft dysfunction	Up regulation miR-155 and miR-181a
Salehi et al, 2020	miR‐20amiR ‐23a miR‐150miR‐200b miR‐503 miR‐663	Serum		74, Liver TX	Acute and chronic liver disease. Successful regeneration in auxiliary liver transplantation	Downregulation of miRNA-23a, -150, - 200b, -503, -663 Upregulation of miRNA20a

Additional information

Funding

This study has been funded by Instituto de Salud Carlos III through the project PI19/00378 (Co-funded by European Regional Development Fund/“A way to make Europe”)